2014-2025 Biotech Valuations:
The decline in private biotech valuations signals a structural, not just cyclical, shift—driven by a reassessment of risk tolerance, expected returns, and capital efficiency
The corrosive effects of dilution - via the compounding impact of multiple +/- 15% follow on financings and 5% annual evergreen option pool expansions….
Understanding how investors use NPV to value drugs at various stages of drug development explains what CBO's and other analyses miss. https://t.co/iCDJeMY2Lb
Imagine a robot helping you with household chores, and if it makes an error, you can just guide it with a gentle push or point it in the right direction. This intuitive system it super user-friendly. https://t.co/RCsZqAUUf9
Support the Future of Inclusive Beauty – The Imperfectionist. One of the most inspiring young female CEOs we have met is launching a groundbreaking beauty brand via @Kickstarter : Luxury makeup celebrating real people. https://t.co/0UjvANDEPT
#inclusivebeauty#Entrepreneurship